NCT03866369View on ClinicalTrials.gov

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

August 27, 2019

Study Completion Date

August 27, 2019

Conditions
Healthy Subjects
Interventions
DRUG

Moxifloxacin

Single oral dose at D-8

DRUG

Placebo

Single oral dose at D-1

DRUG

Lanifibranor

Single daily oral dose during 14 days

DRUG

Placebo

Single daily oral dose during 14 days

Trial Locations (1)

Unknown

Parexel International GmbH, Berlin

Sponsors

Lead Sponsor

Inventiva Pharma

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Inventiva Pharma

INDUSTRY

NCT03866369 - Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose | Biotech Hunter | Biotech Hunter